← All trials
NCT06716619
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2024
- Primary completion
- Dec 19, 2026
- Completion date
- Dec 19, 2027
- First posted
- Dec 4, 2024
- Last posted
- Dec 4, 2024
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou FineImmune Biotechnology Co., LTD.Lead sponsor
- Sun Yat-Sen UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.